X-LINKED RETINITIS PIGMENTOSA
Clinical trials for X-LINKED RETINITIS PIGMENTOSA explained in plain language.
Never miss a new study
Get alerted when new X-LINKED RETINITIS PIGMENTOSA trials appear
Sign up with your email to follow new studies for X-LINKED RETINITIS PIGMENTOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy for inherited blindness shows promise in Long-Term study
Disease control OngoingThis study follows 97 people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss, to see if a one-time gene therapy is safe and helps preserve sight over time. Participants received an injection of a modified virus carrying a working copy of the RPGR…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 09, 2026 08:18 UTC
-
Experimental gene therapy aims to save sight in rare eye disease
Disease control OngoingThis study tests a gene therapy called AGTC-501 in males aged 12 to 50 with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Participants receive one of two doses of the therapy or no treatment, and researchers measure changes in vision over time. The…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated May 09, 2026 08:06 UTC
-
Second-Eye gene therapy trial offers hope for rare vision loss
Disease control OngoingThis study tests a gene therapy given to the second eye in people with X-linked retinitis pigmentosa, a genetic condition that causes progressive vision loss. Participants already received treatment in one eye in an earlier study. The goal is to check safety and whether vision ca…
Matched conditions: X-LINKED RETINITIS PIGMENTOSA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 06, 2026 16:13 UTC